Product logins

Find logins to all Clarivate products below.


Cecilia Klein, PhD

Director for Discovery and Translational Science Consulting

As Global Lead for Clarivate Discovery and Translational Science Consulting Services, Cecilia leads a team of consultants with in-depth knowledge in statistical and machine learning techniques, network, image and multi-OMICs data analysis. They support pharma and biotech customers in the drug discovery process through target and biomarker identification, understanding mechanisms of pathology or drug action and prioritizing candidates for drug repurposing.

Cecilia is expert at making the complex simple and actionable in a timely manner. Her focus is on helping scientists improve decision making and accelerate execution in the area of drug discovery.

Over the past 10+ years working as a computational biologist, she has dealt with virtually every flavor of NGS technologies at every stage of the experimental process: from experimental design through data acquisition to analysis, visualization and interpretation of the results.

Prior to joining Clarivate in 2019, Cecilia completed her PhD in Bioinformatics at the University of Lyon (France) and her Masters in Computational Biology at the National Laboratory of Scientific Computing (Rio de Janeiro, Brazil). She received her Bachelors Degree in Biology from the Federal University of Rio Grande do Sul. She speaks five languages: Portuguese, Spanish, French, English and Catalan. She is also learning Japanese.


arrow_forward
Get in touch with Cecilia

Latest news

News July 10, 2026
Clarivate to Report Second Quarter 2026 Results on July 29, 2026

London, U.K., July 10, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the second…

News July 9, 2026
Clarivate Releases G20 Research and Innovation Scorecard 2026

Tracking global research power, impact and collaboration as G20 priorities shift

News July 6, 2026
Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company’s focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.